UK focused agencies - 2022 edition
This list displays those agencies that told us approximately 80% to 100% of their business was dedicated to advertising, branding, creative and design projects in the UK healthcare sector.
Click on an agency name or logo to view their profile page where you can read what the agency has to say about themselves, view the data they submitted and a breakdown of how their overall position is made up from the different ranking factors. Find out how the list was created and the methodology used here.
| Rank | OverallRank | Name | Awards | Social media | Total agency billings | UK creative healthcare billings | Total staff | Healthcare staff | Age | |
|---|---|---|---|---|---|---|---|---|---|---|
| 31 | bmore |
|
|
|
|
10-24 staff | 10-24 staff | Between 10 and 15 years | ||
| 40 | Brood |
|
|
|
|
10-24 staff | 10-24 staff | Between 3 and 5 years | ||
| 14 | Get Animated Medical |
|
|
|
|
10-24 staff | 10-24 staff | Between 3 and 5 years | ||
| 29 | Hanson Zandi |
|
|
|
|
10-24 staff | 10-24 staff | Over 30 years | ||
| 35 | Learner Adams Bones |
|
|
|
|
10-24 staff | 10-24 staff | Between 10 and 15 years | ||
| 28 | One Vision Health |
|
|
|
|
10-24 staff | 10-24 staff | Between 10 and 15 years | ||
| 13 | PRECISIONeffect London |
|
|
|
|
25-49 staff | 25-49 staff | Over 30 years | ||
| 27 | Salt |
|
|
|
|
10-24 staff | 10-24 staff | Between 5 and 7 years |
This listing was produced in good faith using data supplied by the agencies and data in the public domain. Some data may not have been independently verified by PMLiVE. This is not an exhaustive list of all agencies working in the UK. Find out how the list was created and the methodology used here.
COVID-19 Updates and Daily News
Featured jobs
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
Quick links
Latest intelligence
- The challenges of identifying rare diseases
- With increased awareness and improved diagnosis, more rare diseases are being recognised and this number is likely to increase in the coming years...
- 5 ways we’re enhancing our services to support our clients in 2023
- Fishawack Health CEO Jon Koch explains the new platforms, tools, and services we’re elevating to drive innovation for our clients in 2023....
- ASH 2022: bad blood but big advances
- Five trends from this year’s ASH conference – and why even pop icons can’t compete with the playlist of innovation shaping haematology...
- Europe’s cancer community publishes new report on transforming patient care
- Eli Lilly announces $450m investment in US manufacturing site
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- ASH 2022: bad blood but big advances
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- MIT researchers develop AI model to detect future lung cancer risk
- GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis
- Kite and Arcellx close multiple myeloma collaboration agreement
- The challenges of identifying rare diseases
- Live Webinar: Streamlining Healthcare Delivery Through Digital Care Journeys
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- Boehringer reports positive phase 2 data for spesolimab in generalised pustular psoriasis
- EU outlines measures to mitigate antibiotic shortage across Europe
- The challenges of identifying rare diseases
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- This month in 1917: A tale of two Mercks
Cuttsy + Cuttsy
Here at Cuttsy+Cuttsy, we believe in making the world a better place by bringing trusted, accessible information to all and...